| PM |
Report |
Adjusted Diluted EPS (Q2 2026) |
BEAT |
pred ~$2.09 vs. cons $2.06 |
MEDIUM |
| PM |
Report |
Organic Net Revenue Growth (Q2 2026) |
BEAT |
pred ~5.8% vs. cons 5.0% |
MEDIUM |
| PM |
Report |
U.S. ZYN Shipment Volume (Q2 2026, cans) |
MISS |
pred ~175M vs. cons ~180M |
MEDIUM |
| PM |
Guide |
FY2026 Adjusted Diluted EPS Guidance |
BETTER |
guide ~$8.50 (midpoint of narrowed/raised $8.42-$8.58) vs. cons $8.40 (FY2026) |
MEDIUM |
| PM |
Guide |
Q3 2026 Organic Net Revenue Growth Outlook |
BETTER |
guide ~6.0% vs. cons 5.5% (Q3 2026) |
LOW |
| PM |
Guide |
FY2026 Organic Operating Income Growth Range |
UNCHANGED |
guide 7-9% (~8% midpoint) vs. cons ~7.6% (FY2026) |
MEDIUM |
| PM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.7% |
— |
MEDIUM |
| PM |
Return |
5-day cumulative residual |
+0.1% (FADE) |
A modest EPS/organic-revenue beat plus a small FY EPS guide raise should support an initial positive idiosyncratic pop, but three overhangs likely erode gains into day 5: (1) Japan HTU IMS growth headline deceleration (flagged as mechanical pantry-load reversal) risks an initial negative read that only partially reverses once analysts digest the explanation; (2) U.S. ZYN shipments likely stay below offtake with no concrete ZYN Ultra/FDA approval date, keeping the swing-factor bear case alive and prompting some sell-side trimming of out-quarter ZYN estimates even after a headline beat; (3) the CFO handover from Babeau to Andolina (effective Aug 1) adds a governance/continuity discount that can weigh on flows over the week. Net effect: initial pop fades toward flat as revisions settle on in-line-to-slightly-better full-year math rather than a durable re-rating. |
LOW |